Share this article
Share this article
WALTHAM, Mass., Feb. 3, 2021 /PRNewswire/ Thermo Fisher Scientific, the world leader in serving science, has signed an agreement with JW Therapeutics, a leading cell therapy company, to ensure non-exclusive commercial access to Thermo Fisher s Gibco CTS Dynabeads CD3/CD28.
The agreement will support the clinical development and commercial manufacturing of leading CAR-T (Chimeric Antigen Receptor T-Cells) therapies in China, including JW Therapeutics lead product relmacabtagene autoleucel ( relma-cel ). Relma-cel is an anti-CD19 CAR-T therapy for third-line treatment for relapsed or refractory ( r/r ) B-cell lymphoma. The therapy s new drug application (NDA) has been accepted by China s National Medical Products Administration (NMPA). Relma-cel is expected to be the first CAR-T therapy to be approved as a Category 1 biologics product in China.